Advertisement

Topics

Latest "Asia Hong Kong" News Stories

07:17 EST 11th December 2018 | BioPortfolio

Here are the most relevant search results for "Asia Hong Kong" found in our extensive news archives from over 250 global news sources.

More Information about Asia Hong Kong on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Asia Hong Kong for you to read. Along with our medical data and news we also list Asia Hong Kong Clinical Trials, which are updated daily. BioPortfolio also has a large database of Asia Hong Kong Companies for you to search.

Showing "Asia Hong Kong" News Articles 1–25 of 3,000+

Extremely Relevant

STAT Plus: How is Hong Kong’s biotech experiment going? A Hong Kong Stock Exchange official weighs in

How is Hong Kong's biotech experiment going? We checked in with a senior vice president on the Hong Kong Stock Exchange.


Hansoh Pharma Plans Hong Kong IPO that Could Raise $1-$3 Billion

Hansoh, a China pharma based in Lianyungang, Jiangsu province, has applied to stage an IPO on the Hong Kong exchange. Unlike most companies seeking Hong Kong IPOs, Hansoh is both profitable and established. It claims to be one of the top 30 biopharmas in China, with revenues of $900 million in 2017. Two years ago, when rumors of a Hong Kong IPO first surfaced, it was thought Hansoh's debut would r...

World’s first human case of rat disease discovered – WTOP

WTOPWorld's first human case of rat disease discoveredWTOPBy Meera Senthilingam and Rob Picheta, CNN. (CNN) — For the first time, a case of rat hepatitis E has been discovered in a human in Hong Kong. A 56-year-old man has been diagnosed with the disease, researchers from the University of Hong Kong said.Human rat disease caused by rodents 'bigger than CATS', claims Hong Kong health officialDail...


Hong Kong scientists say new research points to universal antibody drug for HIV

HONG KONG (Reuters) - A team of AIDS researchers in Hong Kong says its new research, tested on mice, indicates a functional cure for HIV, the virus that causes AIDS, eventually leading to a new antibody that could be used for both prevention and trea...

World’s first human case of rat disease discovered – KRON4

KRON4World's first human case of rat disease discoveredKRON4(CNN) -- For the first time, a case of rat hepatitis E has been discovered in a human in Hong Kong. A 56-year-old man has been diagnosed with the disease, researchers from the University of Hong Kong said. It was not previously known the disease could ...Human rat disease caused by rodents 'bigger than CATS', claims Hong Kong health offic...

Premia Partners launches world's first Asia Innovative Technology and Emerging ASEAN Titans ...

HONG KONG, Aug. 5, 2018 /PRNewswire/ -- Premia Partners, the Hong Kong-based investment firm that focuses on ETFs and smart beta solutions, announces the launch Read more...

Premia Partners lanza los primeros fondos cotizados Asia Innovative Technology ETF y Emerging ...

HONG KONG, 5 de agosto de 2018 /PRNewswire/ -- Premia Partners, la empresa de inversión con sede en Hong Kong que se centra en fondos Read more...

First Human Case of Rat Strain of Hepatitis E Seen in Hong Kong

MONDAY, Oct. 1, 2018 -- The first human case of a strain of hepatitis E previously found only in rats was diagnosed in a Hong Kong man who received a liver transplant in May 2017. University of Hong Kong researchers said the 56-year-old man was...

Hong Kong scientists say new research points to 'functional cure' for HIV

HONG KONG (Reuters) - A research team at Hong Kong University’s AIDS Institute says it may have found a "functional cure" to HIV, the virus that causes AIDS, in a major breakthrough that could see a new antibody be used for both prevention and trea...

Premia Partners lança os primeiros Asia Innovative Technology and Emerging ASEAN Titans ETFs ...

HONG KONG, 5 de agosto de 2018 /PRNewswire/ -- A Premia Partners, empresa de investimentos sediada em Hong Kong que foca em ETFs e soluções Read more...

Two US Biopharmas -- Stealth and AOBiome -- File for IPOs on Hong Kong Exchange

Two young Boston-area biotechs have filed with the Hong Kong Exchange to conduct IPOs on the exchange, taking advantage of the new rules allowing pre-revenue companies to list and seeking the high valuations Hong Kong investors offer. Stealth BioTherapeutics and AOBiome Therapeutics are both developing novel drugs that are in (or close to) Phase III trials. The two US biopharmas join two China com...

Axis, Hong Kong Polytechnic University Sign MoU

To establish a joint research center to advance the application of immunotherapy in Hong Kong

X-Ray Pad, a Hong Kong-Based Manufacturer, Launched Custom-Designed Gaming Mouse Pads for Video ...

HONG KONG, Sept. 29, 2018 /PRNewswire/ -- X-Ray Pad, a Hong Kong-based PC accessories manufacturer having its forte in manufacturing mouse pads, playmats, gaming bags Read more...

Hong Kong OKs Zai Lab's ovarian cancer drug

Hong Kong's Department of Health granted approval to Zai Lab's Zejula, or niraparib, as a treatment for adult patients with p -More- 

Cardiovascular Systems’ Stealth 360 Peripheral OAS comes to Hong Kong

The company said that its Stealth 360 peripheral OAS was used to treat a patient in Hong Kong, which marks the first commercial use of the product outside The post Cardiovascular Systems’ Stealth 360 Peripheral OAS comes to Hong Kong appeared first on Compelo Medical Devices.

Innovent Biologics Plans Hong Kong IPO to Raise $423 Million, Despite Global Downturn

China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.

Suzhou's Innovent Rises 19% in First Trading Day on the Hong Kong Exchange

Suzhou's Innovent Biologics climbed 19% higher in its first day of trading on the Hong Kong Exchange, following its IPO last week. The positive reception is the first time investors have driven one of Hong Kong's pre-revenue biopharma IPOs higher in open market trading. Although the anticipation for the pre-revenue channel was very high, the previous three listings closed their first sessions more...

Bank of China (Hong Kong) Limited announces Tender Offer to Purchase for Cash Any and All of ...

HONG KONG, Aug. 30, 2018 /PRNewswire/ -- Bank of China (Hong Kong) Limited (the "Company") hereby announces that it has commenced a tender offer (the Read more...

Cocrystal Pharma to study hepatitis C drug in Hong Kong

US-based biotechnology firm Cocrystal Pharma has signed a clinical trial agreement with Humanity & Health Research Centre in Hong Kong...Read More... The post Cocrystal Pharma to study hepatitis C drug in Hong Kong appeared first on Drug Development Technology.

General Atlantic Invests $150 Million in Asia Holding, a Hospital/Clinic Company

General Atlantic, a global growth equity firm, invested $150 million in Hong Kong Asia Medical Holding. Asia Holding provides cardiovascular healthcare services and operates hospitals under the name Asia Heart. Currently, the company operates two hospitals in Wuhan and Xinjiang. It also co-manages four heart centers including a new one in Hong Kong and another recently acquired center in Japan. Th...

STAT Plus: Can Hong Kong lure biotech without inflating a bubble?

Hong Kong has fewer than 20 experienced bankers who specialize in biotech, but the region's boosters say they're determined to become a hub.

Inter Partner Assistance Hong Kong Ltd. Forms a Partnership With The CareVoice To Provide Fully Digital Health Journeys and Integrated Healthcare Solutions to the Hong Kong Health Insurance Market

HONG KONG–(BUSINESS WIRE)–Inter Partner Assistance Hong Kong Ltd. has partnered with The CareVoice to provide fully digital health journeys and integrated healthcare solutions to the insurance market. Inter Partner Assistance Hong Kong Ltd. maintains an extensive hospital network and has … Continue reading → Cet article

CStone proposes IPO in Hong Kong

CStone Pharmaceuticals proposed to list an initial public offering on the Hong Kong stock exchange.  -More- 

Innovent Completes $421 Hong Kong IPO; Trading Begins in One Week

Innovent Biologics has priced its Hong Kong IPO to raise $421 million, very close to the top of the expected range. The company set its offering price at HK$13.98, just below the top of the range. The successful IPO shows investors are still interested in young China biopharmas, even though the three earlier pre-revenue biotech IPOs in Hong Kong saw their prices slide lower once they began trading...

HKU student wins technology and innovation contest in China

(The University of Hong Kong) Year- 6 medical student Mr Lai Hei-ming from the Li Ka Shing Faculty of Medicine at the University of Hong Kong (HKU) won the 11th China Adolescents Science and Technology Innovation Contest with his breakthrough in the visualisation of human brain tissue at the microscopic level. Mr Lai is one of the 100 young researchers in China to win the award this year and the o...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks